Novo Nordisk stock gets outlook lift from Wegovy pill demand

Published on 11/09/2026 at 12:13 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Novo Nordisk stock is entering a recovery test after the company lifted its 2026 outlook on stronger GLP-1 momentum. Competition remains intense.

What Novo changed

Novo Nordisk raised its 2026 adjusted sales and operating profit outlook to a range of -2% to +2% at constant exchange rates.
Third-quarter adjusted sales rose 4% at constant exchange rates, while adjusted operating profit increased 27%.
Wegovy pill sales reached DKK 5.394 billion as the rollout expanded to eight markets.

Novo-Nordisk, DK0062498333, Illustration mit AI erstellt.

Novo Nordisk lifted its 2026 outlook on Wednesday, November 4, after a stronger-than-expected third quarter and continued demand for its Wegovy pill. The Danish drugmaker now expects adjusted sales growth and adjusted operating profit growth of -2% to +2% at constant exchange rates, compared with the previous range of -6% to 0%. The company said the improvement was driven by higher expectations for GLP-1 product sales.

The figures come from Novo Nordisk in its financial report for the period from January 1 through September 30, 2026. Adjusted third-quarter sales rose 4% at constant exchange rates to DKK 79.195 billion. Adjusted operating profit increased 27% at constant exchange rates to DKK 31.720 billion.

Wegovy pill leads the recovery effort

Wegovy pill sales reached DKK 5.394 billion in the third quarter. The product had launched in the United States, the United Arab Emirates, the United Kingdom and Germany by the end of the quarter, while four additional launches later lifted the total number of markets to eight. Novo Nordisk said it expects the pill to be available in more than 20 markets by the first half of 2027.

Management described the early international launches as encouraging and said the obesity portfolio led growth in both US and international operations. The outlook nevertheless assumes sales growth internationally and a decline in US operations. That mix leaves pricing, market access and competition important factors for the recovery.

Reported profit carries one-off charges

The adjusted improvement does not translate directly into reported operating profit. Reported operating profit fell 9% at constant exchange rates in the quarter, after Novo Nordisk recognised DKK 8.7 billion in non-cash impairment charges related to ziltivekimab and the right-sizing of its manufacturing network. Adjusted figures exclude exceptional and non-recurring items that are not part of normal operations.

Novo Nordisk stock traded at 36.79 euros on Lang & Schwarz at 12:09 CET on Monday, November 9, 2026. Investors can follow the real-time quote of Novo Nordisk stock.

The next major strategic milestone is the planned US launch of CagriSema in early 2027, subject to regulatory approval. For investors, the raised outlook provides support for a recovery case, while the expected US decline and intense obesity-drug competition remain material risks.

Broader market developments are covered in Current market reports.

More news and analyses on Novo Nordisk stock